Just over 4,200 people could be set to benefit after Sparsentan (also known as Filspari and made by Vifor Pharma) was recommended in final draft guidance as an option for treating primary ...

NICE, together with NHS England, remains committed to working with the company to try to reach a long-term deal that will give access to cerliponase alfa to all eligible people after that time.

Given as a once-weekly injection under the skin using a pre-filled syringe or pen, marstacimab is also the first haemophilia B treatment that works by targeting a protein in the blood clotting process ...